Literature DB >> 29038102

ST-Elevation Magnitude Correlates With Right Ventricular Outflow Tract Conduction Delay in Type I Brugada ECG.

Kevin M W Leong1, Fu Siong Ng2, Cheng Yao2, Caroline Roney2, Patricia Taraborrelli2, Nicholas W F Linton2, Zachary I Whinnett2, David C Lefroy2, D Wyn Davies2, Phang Boon Lim2, Sian E Harding2, Nicholas S Peters2, Prapa Kanagaratnam2, Amanda M Varnava1.   

Abstract

BACKGROUND: The substrate location and underlying electrophysiological mechanisms that contribute to the characteristic ECG pattern of Brugada syndrome (BrS) are still debated. Using noninvasive electrocardiographical imaging, we studied whole heart conduction and repolarization patterns during ajmaline challenge in BrS individuals. METHODS AND
RESULTS: A total of 13 participants (mean age, 44±12 years; 8 men), 11 concealed patients with type I BrS and 2 healthy controls, underwent an ajmaline infusion with electrocardiographical imaging and ECG recordings. Electrocardiographical imaging activation recovery intervals and activation timings across the right ventricle (RV) body, outflow tract (RVOT), and left ventricle were calculated and analyzed at baseline and when type I BrS pattern manifested after ajmaline infusion. Peak J-ST point elevation was calculated from the surface ECG and compared with the electrocardiographical imaging-derived parameters at the same time point. After ajmaline infusion, the RVOT had the greatest increase in conduction delay (5.4±2.8 versus 2.0±2.8 versus 1.1±1.6 ms; P=0.007) and activation recovery intervals prolongation (69±32 versus 39±29 versus 21±12 ms; P=0.0005) compared with RV or left ventricle. In controls, there was minimal change in J-ST point elevation, conduction delay, or activation recovery intervals at all sites with ajmaline. In patients with BrS, conduction delay in RVOT, but not RV or left ventricle, correlated to the degree of J-ST point elevation (Pearson R, 0.81; P<0.001). No correlation was found between J-ST point elevation and activation recovery intervals prolongation in the RVOT, RV, or left ventricle.
CONCLUSIONS: Magnitude of ST (J point) elevation in the type I BrS pattern is attributed to degree of conduction delay in the RVOT and not prolongation in repolarization time.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  Brugada syndrome; ajmaline; electrocardiography; electrophysiologic techniques, cardiac; heart ventricles; sodium channels

Mesh:

Substances:

Year:  2017        PMID: 29038102     DOI: 10.1161/CIRCEP.117.005107

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  6 in total

Review 1.  Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest.

Authors:  Serge Sicouri; Charles Antzelevitch
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

2.  Ajmaline-Induced Slowing of Conduction in the Right Ventricular Outflow Tract Cannot Account for ST Elevation in Patients With Type I Brugada ECG.

Authors:  Charles Antzelevitch; Bence Patocskai
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-10

Review 3.  Risk Stratification in Brugada Syndrome: Current Status and Emerging Approaches.

Authors:  Shohreh Honarbakhsh; Rui Providencia; Pier D Lambiase
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06

Review 4.  Validation and Opportunities of Electrocardiographic Imaging: From Technical Achievements to Clinical Applications.

Authors:  Matthijs Cluitmans; Dana H Brooks; Rob MacLeod; Olaf Dössel; María S Guillem; Peter M van Dam; Jana Svehlikova; Bin He; John Sapp; Linwei Wang; Laura Bear
Journal:  Front Physiol       Date:  2018-09-20       Impact factor: 4.566

Review 5.  Brugada Syndrome Manifesting Only During Fever in Patient with Septic Shock Secondary to Post-Obstructive Pneumonia.

Authors:  Kristopher S Pfirman; Corey A White; Abiy Kelil; Hemant C Modi
Journal:  Am J Case Rep       Date:  2018-11-03

Review 6.  Mechanisms of Arrhythmias in the Brugada Syndrome.

Authors:  Michiel Blok; Bastiaan J Boukens
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.